Search
From Germany: Heidelberg University has created a unique platform, hei_INNOVATION, that is meant to encourage its students to become entrepreneurs and then help them achieve their goals along the way
Raoul Haschke, Head of hei_INNOVATION, explains the program and walks us around a workspace that is made available to the students to participate.
Apr 28
From Heidelberg: bioRN Executive Director Julia Schaft describes the world class science happening in the Rhine-Neckar region today and how they are trying to catalyze more biotech companies out of it
She describes the universities, research intitutes, and industry that exists here, and how bioRN is working to connect them together and grow the biotech sector in the region. Plus, comments on the entrepreneurial environment, VC landscape, and more.
Apr 28
From Germany: HepaRegeniX hits a kinase that was discovered at the University of Tübingen to regenerate healthy liver cells when inhibited. They already have phase 1b data in hand from the Mayo Clinic
CEO Elias Paptheodorou walks us through the data and descirbes how this has already been tested (for safety) in five cancer patients who had small portions of their liver resected. The next step is to test it in patients with major resections, and also a randomized phase 2a, both of which the company already has the cash to fund.
Apr 27
From Germany: U.S. listed Immatics was founded in Tubingen and is based on foundational work on PRAME that was done here. A pivotal analysis is scheduled to be triggered this year
Co-Founder & CEO Harpreet Singh walks us through the science of PRAME, which happened here at the University of Tubingen and led to the work the company does today. A pivotal trial for a cell therapy in melanoma will trigger an analysis this year, and Immatics also has bispecific programs and a second generation cell therapy under development.
Apr 27
Biotech's movers for the week of April 20th and a look head at a busy Monday morning for the sector next week
Reviewing some of biotech's biggest movers of the week including Inhibrx (Reuters is reporting that Merck is interested), Agios, Spruce, and more. Plus, looking ahead to key data readouts on Monday morning from Intellia and Compass Therapeutics.
Apr 25
Unnatural Products has built its expertise in developing macrocyclic peptides. It had already landed four major partnerships before raising its series B in March
Co-Founder & CEO Cameron Pye walks us through the science of macrocyclic peptides, and discusses the for partnerships (BridgeBio, argenx, Merck, and Novartis). The company raised a $45M series B in March.
Apr 23
Clear Street Senior Biotech Analyst Kaveri Pohlman discusses names that she covers and previews two 2Q data announcements
She discusses Structure, Enliven, Palvella, Moonlake, Evommune, and Oruka. Chapters General sentiment - 1:17 Structure Therapeutics - 4;29 Enliven - 7:50 Palvella - 10:43 Moonlake - 12:47 Evommune - 15:02 Oruka - 16:39
Apr 23
Population Heath Partners Managing Partner and former Metsera CEO Whit Bernard shares his take on the state of the obesity market and more
He shares his thoughts on recent data we have seen from mechanisms such as INHBE and amylin, why he's a big believer in oral therapies, and what other ares of biotech excite him today.
Apr 23
Off-Target Effects Episode 6: BridgeBio Founder & CEO Neil Kumar discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term
He and Matt talk about portfolio construction, and the dynamics of taking on the right capital structure throughout different phases of a company's lifecycle. Neil shares early learnings from the commercial launch of Attruby, how being a commercial stage company can impact culture, and why he created the early-stage R&D focused sister company Gondola. Plus, discussing talent, intellectual property, and more. Chapters The hub and spoke model - 0:41 Equity structure - 5:43 Putt
Apr 23
Replimune's Chairman discusses FDA's polarizing decision to not approve the company's melanoma treatment after a new review. He says they have filed a FOIA request to learn more about FDA's process
Philip Astley-Sparke describes the timeline of development of this oncolytic immunotherapy, his impression of FDA's review process and decisions around it, and the status of where the treatment stands today.
Apr 22
Invivyd develops monoclonal antibodies to prevent or treat infectious diseases. This approach could be useful in tamping down the measles outbreaks that have been occurring due to under-vaccination
CSO Robert Allen describes Invivyd's approach and why antibodies can be a good approach, especially as it relates to being resistant to viral evolution. He walks us through the science and some potential use cases. Chapters His career - 0:00 A monoclonal approach - 1:50 Measles - 7:28 The science behind Invivyd - 11:10 Pandemic preparedness - 19:24 Advice to students - 20:50
Apr 22
Bay Area based Epia Neuro exited stealth earlier this month with the goal of developing a device implanted in the skull that could act as an interface to a glove to helps stroke survivors regain grip
Co-Founder & CEO Michel Maharbiz describes the idea behind this brain-computer interface (BCI), which is not yet in human trials. While cautioning that much work and learning lies ahead, he sees the possibility that such a system could also improve a patient's rehab and might potentially have further uses in diseases of cognitive decline.
Apr 21
Peter Hotez discusses tropical disease, the importance of science communication, career advice for young scientists, and more
He describes his work in tropical disease, and how climate change has been elevating it in areas like the Gulf Coast of the United States. Plus, the importance of elevating scientists, what he has found works best for communicating with the public, and why he disagrees with the idea of 'hunkering down' until a day that science funding might rebound in the U.S.. Chapters Elevating scientists - 0:35 Tropical diseases - 7:20 Science communications - 15:30 Career advice for young
Apr 21
Physican and Biotech Investor Adam May reacts to this morning's 52 week Rezpeg data in alopecia from Nektar
He shares his thoughts on the data, the competitive profile of this IL-2 Treg therapy vs JAK inhibitors, and how the overall platform looks for other I&I conditions.
Apr 20
BioVenture VoiCes Episode 38: Deerfield Management's Jason Fuller
He discusses his education and joining the Langer Lab at MIT, early experiences in venture, including at Third Rock and NEA, and gaining operational experience at Jounce before joining Deerfield. Plus, areas that interest him today and how he thinks about AI. Chapters Intro and early life - 0:42 MIT / Langer Lab - 7:23 Third Rock - 10:20 Jounce - 22:59 NEA - 30:10 Joining Deerfield - 39:05 Deerfield today - 42:35 Areas of interest - 51:14 AI - 57:10 Healthtech and Medtech - 1
Apr 20
10x Genomics today is announcing Atera, its new in situ spatial transcriptomics platform
Co-Founder and CEO Serge Saxonov walks us through the platform, which can process up to 800 whole-transcriptome samples per year (1 cm² each) on a single instrument, scaling to thousands of samples per year for targeted assays, and has single-cell level sensitivity.
Apr 18
Biotech's movers for the week of April 13th and a look ahead to what is on tap for the sector next week
Reviewing some of biotech's biggest moves over the last week, including InflaRx, Revolution Medicines, Replimune, Allogene, and more.
Apr 18
Is this analyst the world's biggest bear on the weight loss space? After downgrading Lilly to a sell rating, HSBC's Rajesh Kumar discusses why he thinks pricing factors are being under-appreciated
Plus, discussions on key trial readouts outside of obesity: eplontersen, Lp(a), oral IL-23, and milvexian. Chapters Lilly - 0:48 Novo - 5:15 Zealand - 8:50 AstraZeneca / eplontersen - 10:44 Lp(a) / Novartis, Amgen, Lilly - 15:47 IL-23 / JNJ , Protagonist - 19:24 Milvexian / JNJ, Bristol 22:11 Note: A different division of HSBC, HSBC Innovation Banking, is a sponsor of BiotechTV
Apr 17
Reverb Therapeutics Co-Founder & CEO David de Graaf and antibody expert Jonathan Davis discuss the science of bispecifics and multispecifics and what the future holds for these modalities
They walk us through the history of bispecifics, which have been talked about since the early 2000's, and the use cases for them today. Plus, a deep dive into the science, which includes discussing your body's reaction to then, affinity & avidity, CMC, and 'bead-on-a-string' approaches that some have used lately. Finally, a discussion of what the future holds. Chapters Intros - 0:25 Introduction to bispecifics - 3:34 Multispecifics - 8:25 Use cases - 10:39 Your body's reactio
Apr 16
Raymond James Biotech Innovation Symposium: Biotech Analyst Tiago Fauth shares his read on the mood of investors and discusses companies he covers
He discusses Praxis, Insmed, Ionis, PTC Therapeutics, Rapport, and United Therapeutics. Coverage brought to you by
Apr 14
.png){kind=logo}
